Wuhan Easy Diagnosis Biomedicine Co Ltd
SZSE:002932
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/GP
Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.
Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.
Valuation Scenarios
If EV/GP returns to its 3-Year Average (5.2), the stock would be worth ¥3.95 (77% downside from current price).
| Scenario | EV/GP Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 22.2 | ¥16.97 |
0%
|
| 3-Year Average | 5.2 | ¥3.95 |
-77%
|
| 5-Year Average | 0.5 | ¥0.37 |
-98%
|
| Industry Average | 8.4 | ¥6.42 |
-62%
|
| Country Average | 13.6 | ¥10.38 |
-39%
|
Forward EV/GP
Today’s price vs future gross profit
Peer Comparison
| Market Cap | EV/GP | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd
SZSE:002932
|
3.7B CNY | 22.2 | 524.8 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
162.6B USD | 23.6 | 56.9 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
155.4B USD | 6.1 | 24.8 | |
| US |
|
Stryker Corp
NYSE:SYK
|
112.7B USD | 7.6 | 34.7 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
102.7B USD | 5.3 | 22.3 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
83.8B USD | 6.5 | 23.5 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
48.8B USD | 9.2 | 44.5 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
39.3B EUR | 5.2 | 18.6 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
45.2B USD | 17.1 | 42.7 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
42.5B USD | 5.8 | 24.2 | |
| US |
|
Resmed Inc
NYSE:RMD
|
29.9B USD | 8.8 | 20.1 |
Market Distribution
| Min | 0 |
| 30th Percentile | 8 |
| Median | 13.6 |
| 70th Percentile | 23.3 |
| Max | 17 898 541.1 |
Other Multiples
Wuhan Easy Diagnosis Biomedicine Co Ltd
Glance View
Wuhan Easy Diagnosis Biomedicine Co., Ltd. is engaged in the manufacturing and selling of the Diagnosis Biomedicine related equipment. The company is headquartered in Wuhan, Hubei and currently employs 1,144 full-time employees. The company went IPO on 2018-07-10. The firm's main products are POCT rapid diagnostic reagents, which can be divided into six categories: infectious diseases, cardiovascular and cerebrovascular diseases, kidney diseases, diabetes, gynecology and eugenics, and health checkups. The firm's main products are mainly used in domestic hospitals, health service centers, community clinics, medical examination centers and other medical institutions.
